Page 133 - 2021_06-Haematologica-web

Regulation of F8 promoter activity
promotes angiogenesis as well as endothe- lial apoptosis. Ann N Y Acad Sci. 2001;947:117-123.
31. Takahashi K, Sawasaki Y, Hata J-I, Mukai K, Goto T. Spontaneous transformation and immortalization of human endothelial cells. Vitr Cell Dev Biol. 1990;26(3):265-274.
32. Basuyaux JP, Ferreira E, Stéhelin D, Butticè G. The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA- dependent and -independent manner. J Biol Chem. 1997;272(42):26188-26195.
34. Chavez A, Scheiman J, Vora S, et al. Highly efficient Cas9-mediated transcriptional pro- gramming. Nat Methods. 2015; 12(4):326- 328.
35.Chen Y, Pikkarainen T, Elomaa O, et al. Defective microarchitecture of the spleen marginal zone and impaired response to a thymus-independent type 2 antigen in mice lacking scavenger receptors MARCO and SR-A. J Immunol. 2005;175(12):8173-8180.
36. Nicklin SA, Reynolds PN, Brosnan MJ, et al. Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension. 2001;38(1):65- 70.
37. Pierce GF, Iorio A. Past, present and future of haemophilia gene therapy: from vectors and
transgenes to known and unknown out-
comes. Haemophilia. 2018;24 Suppl 6:60-67. 38. Dejana E, Taddei A, Randi AM. Foxs and Ets in the transcriptional regulation of endothe- lial cell differentiation and angiogenesis. Biochim Biophys Acta. 2007;1775(2):298-
312.
39. Poisson J, Lemoinne S, Boulanger C, et al.
Liver sinusoidal endothelial cells: physiology and role in liver diseases. J Hepatol. 2017;66(1):212-227.
40. Li Y, Zhou QL, Sun W, et al. Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activa- tion. Nat Cell Biol. 2015;17(10):1327-1338.0
41. Poon GMK, Kim HM. Signatures of DNA target selectivity by ETS transcription fac- tors. Transcription. 2017;8(3):193-203.
42. Lange AM, Altynova ES, Nguyen GN, Sabatino DE. Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice. Mol Ther Methods Clin Dev. 2016;3:16064.
43. Nougier C, Roualdes O, Fretigny M, et al. Characterization of four novel molecular changes in the promoter region of the factor VIII gene. Haemophilia. 2014;20(2):149-156.
44.Arimoto J, Ikura Y, Suekane T, et al. Expression of LYVE-1 in sinusoidal endothe- lium is reduced in chronically inflamed
human livers. J Gastroenterol. 2010;45(3):
317-325.
45. Merlin S, Cannizzo ES, Borroni E, et al. A
novel platform for immune tolerance induc- tion in hemophilia A mice. Mol Ther. 2017;25(8):1815-1830.
46. DeLeve L, Maretti-Mira A. Liver sinusoidal endothelial cell: an update. Semin Liver Dis. 2017;37(04):377-387.
47. Schwachtgen JL, Janel N, Barek L, et al. Ets transcription factors bind and transactivate the core promoter of the von Willebrand fac- tor gene. Oncogene. 1997;15(25):3091-3102.
48. Lelièvre E, Mattot V, Huber P, Vandenbunder B, Soncin F. ETS1 lowers capillary endothe- lial cell density at confluence and induces the expression of VE-cadherin. Oncogene. 2000;19(20):2438-2446.
49. George LA, Ragni MV, Samelson-Jones BJ, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of an investi- gational AAV-mediated gene therapy for hemophilia a. Blood. 2017;130(Suppl 1):S604.
50. Chuah MK, Petrus I, De Bleser P, et al. Liver- specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non- human primates. Mol Ther. 2014;22(9): 1605-1613.
haematologica | 2021; 106(6)
1635